

Remarks

Claims 1-9 and 14-18 stand rejected under 35 USC 103(a) as allegedly being obvious in view of Tewari *et al.*, *Anorg. Chem. Org. Chem.*; 35(1): pp 95-98 (1980) and Tagaki *et al.*, *J. Am. Chem. Soc.*; 105(14): pp 4676-4684 (1983), individually in view of King, *Med. Chem. Principle and Practice*; pp 206-208 (1994). Without admitting that the pending claims were in fact obvious in view of the cited art, Applicants have proposed amendments herein pursuant to an interview with the Examiner, in an effort to expedite prosecution of the present case.

Basis for each of the newly submitted claims may be found in the original specification and claims. For example, basis for new claim 24 may be found in previous claims 1, 6 and 16. Basis for new claims 25-28 may be found in previous claims 2-5, respectively. Basis for new claims 29 and 30 may be found in previous claims 7 and 8. Basis for new claim 31 may be found in previous claims 9 and 14. Basis for new claims 32-34 may be found in previous claims 10, 11, and 17, respectively. Basis for new claim 35 may be found in the Examples disclosed in the specification, and basis for new claim 36 may be found in previous claim 18.

The newly submitted claims narrow the scope of the claimed invention, thus, Applicants respectfully submit that the present amendment does not encompass new matter. Applicants courteously request entry of the present amendments and reconsideration of the present case. In the event the Examiner intends to once again reject the present invention under 35 U.S.C. §103(a), or if verbal discussion would be of any assistance in advancing prosecution of the present application, Applicants' undersigned attorney invites the Examiner to contact him at the number provided.

Respectfully submitted,

/Alexander Wilson/

Alexander Wilson
Attorney for Applicants
Registration No. 45,782
Phone: 317-277-0190

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288

June 17, 2008